# A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

Study · id `cardio:ct-nct01477853` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01477853](<https://clinicaltrials.gov/study/NCT01477853>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01477853

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 166 participants.

## Technical summary

Registry record NCT01477853. Randomized; double masking; primary purpose treatment. Start 2011-10-24 (actual); primary completion 2012-12-04 (actual). Results posted on 2016-10-05.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 166 participants (enrolled count; ClinicalTrials.gov record NCT01477853, source copy `cardio:ctgov-nct01477853-2018-07-26`, retrieved 2026-10-26)
- Started: 2011-10-24 (actual) (ClinicalTrials.gov record NCT01477853, source copy `cardio:ctgov-nct01477853-2018-07-26`, retrieved 2026-10-26)
- Primary completion: 2012-12-04 (actual) (ClinicalTrials.gov record NCT01477853, source copy `cardio:ctgov-nct01477853-2018-07-26`, retrieved 2026-10-26)
- Completion: 2012-12-04 (actual) (ClinicalTrials.gov record NCT01477853, source copy `cardio:ctgov-nct01477853-2018-07-26`, retrieved 2026-10-26)
- Results first posted: 2016-10-05 (ClinicalTrials.gov record NCT01477853, source copy `cardio:ctgov-nct01477853-2018-07-26`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01477853-2018-07-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Atorvastatin
- Intervention (Other): Placebo to sitagliptin
- Intervention (Other): Placebo to atorvastatin
- Intervention (Drug): Metformin (open-label)
- Intervention (Drug): Glimepiride (open-label)
- Intervention (Drug): Glimepiride (double-blind)
- Intervention (Drug): Placebo to glimepiride
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: c051278cca7f50b2686c383cfdb03500bcc0515348c8b53bd1052d0d3383420c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
